AN2 Therapeutics, Inc.

ANTX

Healthcare Biotechnology

EPS
+14.3%
Free cash flow
+7.91%

Quarter to June 2026, against a year earlier

4.00 0.04 +1.01%
Market cap
$150.9M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.5×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(50.12%) (44.56%) (52.14%) (45.91%)

+8 more TTM periods

ROA
(46.06%) (40.93%) (45.67%) (41.21%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(48.75%) (42.17%) (68.68%) (59.46%)
Free Cash Flow per Share
(0.69) (0.92) (0.99) (0.99)
Free Cash Flow
(30.68) (31.28) (29.83) (29.87)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026